The corporate reversed roughly $3.5 billion in income associated to the expected return of 6.5 million doses of its Covid drug, Paxlovid, from the U.S. authorities. That hit is lower than the $4.2 billion Pfizer initially anticipated for the return of practically 8 million doses of Paxlovid.
Pfizer’s Covid vaccine raked in $5.36 billion in income for the quarter, down 53% from the identical interval final 12 months. Analysts had anticipated the shot to herald $4.99 billion in gross sales, in line with FactSet estimates.
The outcomes come as Pfizer tries to blunt the fast decline of its Covid enterprise, which noticed demand plummet to new lows and transitioned to the business market within the U.S. final 12 months. As income suffers, the corporate is making an attempt to enhance its backside line and increase investor confidence by a broad $4 billion cost-cutting plan.
This is what Pfizer reported for the fourth quarter in comparison with what Wall Avenue was anticipating, based mostly on a survey of analysts by LSEG, previously often known as Refinitiv:
- Earnings per share: 10 cents per share adjusted vs. lack of 22 cents anticipated
- Income: $14.25 billion vs. $14.42 billion anticipated
The pharmaceutical large additionally reiterated its full-year 2024 guidance, which it first outlined in mid-December.
Pfizer expects income to return in between $58.5 billion and $61.5 billion this 12 months, which incorporates roughly $8 billion in income from its Covid merchandise and contributions from its lately closed acquisition of most cancers drug developer Seagen.
The corporate expects to e-book adjusted earnings of $2.05 to $2.25 per share.
Pfizer recorded fourth-quarter income of $14.25 billion, down 41% from the identical interval a 12 months in the past, as a result of plunge in gross sales of its Covid merchandise.
For the fourth quarter, Pfizer booked a web lack of $3.37 billion, or 60 cents per share. That compares to a web earnings of $4.99 billion, or 87 cents per share, in the course of the same period a 12 months in the past.
Excluding sure objects, the corporate’s posted earnings per share of 10 cents for the quarter.
Nonetheless, Pfizer’s Covid enterprise had a dismal 2023.
Income from its Covid vaccine and Paxlovid got here in at $12.5 billion in 2023. That is down 78% from their $57 billion peak in 2022.
Excluding Covid merchandise, Pfizer stated income for the fourth quarter grew 8% operationally.
The corporate stated that progress was partly fueled by its new vaccine in opposition to respiratory syncytial virus, which entered the market in the course of the third quarter for seniors and expectant moms. The shot, often known as Abrysvo, posted $515 million in gross sales for the fourth quarter.
The corporate stated income additionally bought a lift from robust gross sales of Vyndaqel medicine, that are used to deal with a sure kind of cardiomyopathy, a illness of the guts muscle. These medicine booked $961 million in gross sales, up 41% from the fourth quarter of 2022.
Pfizer additionally stated its blood thinner Eliquis, which is co-marketed by Bristol Myers Squibb, helped drive that progress. The drug posted $1.61 billion in income for the quarter, up 9% from the identical interval a 12 months in the past. Analysts had anticipated Eliquis to rake in $1.52 billion in gross sales, in line with FactSet.
One non-Covid product class fared worse than Pfizer hoped. A gaggle of photographs to guard in opposition to pneumococcal pneumonia introduced in $1.60 billion in gross sales for the fourth quarter. That was down 8% from the identical quarter a 12 months in the past because of decrease demand and what the corporate referred to as “unfavorable timing of buyer orders.” Analysts had anticipated that group of photographs to e-book $1.97 billion in gross sales, in line with FactSet.
Wells Fargo analyst Mohit Bansal stated the disappointing gross sales for that group of photographs, which Pfizer calls the Prevnar household, could possibly be a priority.
Bansal famous that Merck has provided encouraging commentary on prospects for its personal pneumococcal pneumonia vaccine franchise, so he expects Pfizer to obtain questions throughout its fourth-quarter earnings name about the way it plans to defend that a part of its enterprise.
The outcomes cap a rocky 12 months for a corporation that when noticed revenue soar after it delivered the world’s first Covid vaccine.
Shares of Pfizer fell roughly 40% in 2023 as demand for its shot and different Covid merchandise plummeted worldwide, inflicting the corporate to dramatically slash its full-year revenue forecast, document multi-billion greenback fees associated to inventory write-offs and launch a sweeping cost-cutting program.
What’s extra, Pfizer’s future within the booming weight reduction drug market started to look bleak final month. The corporate scrapped a twice-daily version of its experimental weight reduction capsule after sufferers with weight problems taking the drug misplaced vital weight however had hassle tolerating the drug in a mid-stage scientific research.
Traders are ready for the corporate to unveil information on a once-daily type of that drug, referred to as danuglipron, in the course of the first half of the 12 months.
Pfizer hopes its $43 billion acquisition of Seagen, which officially closed in the course of the fourth quarter, will restore investor confidence. Final month, the corporate made it clear that it was doubling down on most cancers remedies after it revealed plans to create a new oncology division that features Seagen in early 2024.
However Wall Avenue remains to be skeptical about whether or not Pfizer can flip issues round: The corporate’s inventory is already down greater than 4% for the 12 months, placing its market worth at roughly $155 billion.
Pfizer will maintain an earnings name with traders at 10 a.m. ET on Tuesday.